Eli Lilly and Company (NYSE:LLY) Shares Bought by Independence Bank of Kentucky

Independence Bank of Kentucky lifted its position in Eli Lilly and Company (NYSE:LLYFree Report) by 25.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,187 shares of the company’s stock after acquiring an additional 1,062 shares during the quarter. Eli Lilly and Company accounts for approximately 1.1% of Independence Bank of Kentucky’s holdings, making the stock its 18th largest position. Independence Bank of Kentucky’s holdings in Eli Lilly and Company were worth $3,024,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. JGP Wealth Management LLC grew its stake in Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after purchasing an additional 16 shares in the last quarter. Cassia Capital Partners LLC grew its stake in Eli Lilly and Company by 1.8% in the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after purchasing an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC grew its stake in Eli Lilly and Company by 2.8% in the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after purchasing an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC grew its stake in Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after purchasing an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. grew its stake in Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 180,667 shares of company stock worth $116,186,189. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Citigroup boosted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Barclays boosted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $700.00.

Check Out Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Trading Up 1.6 %

Eli Lilly and Company stock opened at $776.31 on Thursday. The business has a 50 day moving average price of $745.17 and a two-hundred day moving average price of $643.27. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market cap of $737.62 billion, a price-to-earnings ratio of 133.85, a price-to-earnings-growth ratio of 1.68 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $351.27 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.09 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 12.42 EPS for the current year.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.